Prabotulinumtoxin A biosimilar by AEON Biopharma for Migraine: Likelihood of Approval

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Migraine.

Digital health: a case of mistaken identity

History and literature are replete with cautionary tales on the dangers of pretending to be someone — or something — you aren’t. Many digital health

May 22, 2024

Court grants FTC injunction over IQVIA’s deal with Propel Media and DeepIntent

A federal judge granted a preliminary injunction to the Federal Trade Commission over IQVIA’s proposed acquisition of Propel Media and its data-driven healthcare marketing subsidiary

January 3, 2024

Medartis 2023 half-year results presentation – Biotech Investments

Medartis Holding AG / Key word(s): Half Year Results Medartis 2023 half-year results presentation 25.07.2023 / 09:00 CET/CEST INVITATION │ AUDIO WEBCAST We are pleased

July 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.